Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172322 | 1.00 | MGAM (0.38) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL2915906 | 0.90 | POLB (0.37) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL2911153 | 0.85 | POLB (0.38) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL27801248 | 0.83 | ALDH1A1 (0.38) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL23389921 | 0.82 | TSHR (0.33) | MGAMGAASIMGAM2 | |
| SCHEMBL122593 | 0.82 | TSHR (0.33) | MGAMGAASIMGAM2 | |
| SCHEMBL5479797 | 0.81 | ALDH1A1 (0.34) | ALDH1A1MAPTPKM | |
| SCHEMBL28783772 | 0.81 | CYP1A2 (0.42) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL2910528 | 0.80 | MGAM (0.41) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL18655990 | 0.80 | GAA (0.41) | MGAMGAASIMGAM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115318113-B | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2023-10-31 | — | — | CN | claimed |
| CN-115318113-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2022-11-11 | — | — | CN | claimed |
| CN-101641350-A | Dibenzo [ b ] | ARYX THERAPEUTICS INC US | 2010-02-03 | — | — | CN | claimed |
| CN-115318113-B | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-115318113-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-103214473-A | Dibenzo[b,f][1,4]oxazapine compounds | ARYX THERAPEUTICS INC | 2013-07-24 | — | — | CN | disclosed |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2137180-B1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2137180-A1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | Aryx Therapeutics, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| EP-0582164-B1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | BRISTOL MYERS SQUIBB CO (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5382584-A | Antiischemic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0582164-A1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | Bristol-Myers Squibb Company (US) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | MGAM 4454/4885GAA 3552/4885SI 2326/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | MGAM 4648/4885GAA 3879/4885SI 927/4885 |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | MGAM 4072/4885GAA 1058/4885SI 1847/4885 |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | MGAM 1384/4885GAA 4731/4885SI 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.